Liquidia (NASDAQ:LQDA) Shares Gap Up to $14.75

Liquidia Co. (NASDAQ:LQDA - Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $14.75, but opened at $15.49. Liquidia shares last traded at $14.88, with a volume of 191,468 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright raised their target price on shares of Liquidia from $16.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, March 14th. LADENBURG THALM/SH SH increased their price target on Liquidia from $15.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, December 21st. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Liquidia in a research note on Monday. Bank of America raised their target price on Liquidia from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, December 21st. Finally, Wedbush reissued an "underperform" rating and issued a $3.00 price target on shares of Liquidia in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Liquidia Trading Up 1.2 %

The stock has a 50-day moving average of $14.28 and a two-hundred day moving average of $10.22. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -12.40 and a beta of 0.14.

Insider Buying and Selling

In other Liquidia news, insider Jason Adair sold 4,657 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.81, for a total transaction of $73,627.17. Following the sale, the insider now directly owns 108,640 shares of the company's stock, valued at approximately $1,717,598.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Jason Adair sold 4,657 shares of Liquidia stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.81, for a total transaction of $73,627.17. Following the completion of the sale, the insider now owns 108,640 shares of the company's stock, valued at $1,717,598.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Michael Kaseta sold 12,166 shares of Liquidia stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $15.82, for a total value of $192,466.12. Following the sale, the chief financial officer now owns 318,181 shares of the company's stock, valued at $5,033,623.42. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,605 shares of company stock valued at $862,904. Company insiders own 31.60% of the company's stock.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Findell Capital Management LLC acquired a new position in shares of Liquidia during the 4th quarter valued at about $25,095,000. State Street Corp lifted its stake in shares of Liquidia by 861.0% in the second quarter. State Street Corp now owns 1,448,211 shares of the company's stock worth $6,314,000 after buying an additional 1,297,509 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of Liquidia during the 4th quarter worth $12,331,000. Kynam Capital Management LP grew its stake in Liquidia by 34.9% in the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company's stock valued at $32,461,000 after buying an additional 698,324 shares during the last quarter. Finally, Beryl Capital Management LLC bought a new position in Liquidia in the 3rd quarter worth $3,135,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).